The Face of Change at EMEA
Executive Summary
Thomas Lönngren, executive director of the EMEA, talks about how the agency is adapting to changing circumstances such as EU enlargement, new technologies-and a sharp drop in new drug applications this year.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?